I am 35 with ITP for 14 months. How do I manage bleeding?

Question

Hello doctor,

I am 35 years old, and was diagnosed with chronic ITP 14 months ago after my platelet count dropped to 8,000/μL during routine bloodwork.

My most recent CBC shows a platelet count of 22,000/μL despite ongoing treatment, which is still dangerously low.

I am currently taking Prednisone 20 mg daily, but my endocrinologist is concerned about the long-term effects of steroids.

I have gained 25 pounds, and my bone density scan shows early osteopenia. My anti-platelet antibodies are strongly positive, and my peripheral blood smear confirms isolated thrombocytopenia with large platelets.

I experience frequent nosebleeds lasting over 30 minutes, heavy menstrual periods that have required hospitalization twice, and I bruise from the slightest touch.

Just last week, I had a gum bleed that would not stop, and I had to go to the ER for a platelet transfusion. My hematologist has mentioned trying Rituximab or even a splenectomy, but I am afraid of the risks associated with immunosuppression and surgery. I have also heard about thrombopoietin receptor agonists like Eltrombopag.

The constant fear of bleeding is affecting my daily life—I cannot exercise, play with my kids, or perform normal household tasks.

What are the latest treatment options available? Is there hope for achieving a durable remission without long-term immunosuppression?

Please help.

Answer 1

Hello,

Welcome to icliniq.com.

I understand your concern.

I want to reassure you that while ITP (immune thrombocytopenic purpura) can be challenging, there are evolving treatment options offering real hope beyond long-term steroids, which, as you are experiencing, carry considerable side effects like weight gain, osteopenia, and metabolic complications.

Given your persistently low platelet count, bleeding symptoms, and poor response to corticosteroids, second-line therapies are warranted. Rituximab, a monoclonal antibody that targets B-cells, has shown good short- to mid-term response rates (50 to 60 percent), though it does carry a risk of immunosuppression.

Splenectomy, while potentially curative in about two-thirds of patients, is indeed invasive and not without surgical and infectious risks, particularly in adults.

Thrombopoietin receptor agonists (TPO-RAs) such as Eltrombopag and Romiplostim are excellent steroid-sparing alternatives. They stimulate platelet production rather than suppress the immune system, and many patients experience significant and sustained improvement in platelet counts with manageable side effects.

These agents are increasingly used as second-line or even first-line therapy in steroid-refractory ITP, and some patients achieve treatment-free remission after a period of use.

Given your bleeding burden and current platelet level, I strongly recommend discussing initiation of a TPO-RA (thrombopoietin receptor agonist) with your hematologist. They can also reassess the appropriateness of combining it with a short course of Rituximab or other agents like Fostamatinib in refractory cases.

In the meantime, avoid NSAIDs (nonsteroidal anti-inflammatory drugs), alcohol, and activities with high bleeding risk, and ensure vaccinations are up to date if splenectomy is eventually considered. While ITP requires careful management, newer therapies mean that remission or safe long-term control is a realistic goal.

I hope this has helped you.

Please feel free to reach out to me again if you have further queries.

Thank you.